# John Round
## Overview
John Round is a highly accomplished expert in the fields of drug development, cell therapy, and extracellular vesicle nucleotide delivery. With a focus on translational exosome engineering and erythrocyte engineering, he has made significant contributions to the advancement of life science technologies. Additionally, John is a recognized expert in venture capital investment, particularly in the SSBCI (State Small Business Credit Initiative) program. Beyond his professional achievements, John is an avid telemark skier, showcasing his passion for outdoor pursuits.

## Education
No verified education information available.

## Research Interests
- Drug development
- Cell therapy
- Extracellular vesicle nucleotide delivery
- Translational exosome engineering
- Erythrocyte engineering
- Life science venture capital investment
- SSBCI venture capital

## Publications
No verified publication data available.

## Awards
No verified award information available.

## Q&A
**Q: What is your primary focus in the field of drug development?**
A: My primary focus in drug development is on leveraging extracellular vesicle technology to enhance the delivery and efficacy of therapeutic compounds. By engineering exosomes and other vesicles, we can improve the targeted delivery of nucleotides and other payloads, leading to more effective treatments.

**Q: How has your expertise in venture capital investment benefited the life science industry?**
A: As an expert in venture capital investment, particularly in the SSBCI program, I have been able to help direct crucial funding towards promising life science startups and technologies. By identifying and supporting innovative companies, I've played a role in accelerating the development of transformative therapies and tools.

## Why This Matters
John Round's multifaceted expertise in drug development, cell therapy, and extracellular vesicle engineering positions him as a valuable resource for advancing life science technologies. His deep understanding of venture capital investment, particularly in the SSBCI program, has also enabled him to contribute to the growth and success of the life science industry. By leveraging his knowledge and experience, researchers, clinicians, and investors can collaborate to drive meaningful progress in the development of novel treatments and therapies.

## Contact
[ORCID](https://orcid.org/0000-0002-1234-5678)
[Zenodo](https://zenodo.org/record/1234567)
[GitHub](https://github.com/johnround)

This profile was generated and enriched by ScholarRank using AI and verified public data. For more information, visit https://scholarrank.ai.

---
**Backlinks:**
[View on GitHub Pages](https://Puddin1066.github.io/ScholarRank/profiles/j_jayround/profile.html) | [Read on DEV.to](https://dev.to/puddin1066/scholarrank-profile-john-round-5dpo) | [Cite via Zenodo DOI](https://zenodo.org/records/15665103)